ILMN

Illumina, Inc.

September 24, 2026 · intraday

Rarity

1.54

Peak move

+8.72%

Float cap

$39.0B

Illumina provides sequencing- and array-based solutions for genetic and genomic analysis. Its integrated systems, consumables, and analysis tools are used by genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, diagnostic laboratories, and consumer genomics firms. The company serves research, applied, and clinical markets, including oncology, genetic health, and reproductive health.

• index_rebalanceSep 22

  Illumina was added to the S&P 500 Equal Weighted Index and removed from the Russell Small Cap Comp Value Index in the September quarterly rebalance, prompting index-tracking funds to adjust holdings.

  Websimplywall.stWebsimplywall.st
• insider_saleSep 21 · 03:36 ET

  Illumina director Keith Meister sold 119,501 shares at an average price of $218.40 for about $26.1 million on September 4, leaving him 770,350 shares.

  Webmarketbeat.com
• index_rebalanceSep 4

  S&P Dow Jones Indices announced Illumina would join the S&P 500 before the open on Sept 21, 2026, replacing Builders FirstSource (BLDR), as part of the quarterly rebalance disclosed Sept 4, 2026.

  Webpress.spglobal.com
• product_launchJun 7 · 14:08 ET

  Illumina and Integrated DNA Technologies announced a collaboration, alongside the fireflyGO automation platform with SPT Labtech and a new whole-genome-based MRD research kit for oncology.

  Webnz.finance.yahoo.com
• product_launchMay 28

  Illumina launched a whole-genome sequencing research workflow for molecular residual disease detection with early access for select clinical research partners, about five days processing, 10 ppm analytical sensitivity and DRAGEN analysis at 99.5% specificity, with broader commercial launch planned for next year.

  Webttmblog.com